In addition, incretin-based therapies may slow the progression or delay the onset of T2DM in patients with prediabetes, possibly by preserving β-cell function and mass and thereby helping to maintain good long-term metabolic control (16). This evidence concerns the gene GCG and type 2 diabetes mellitus.